Osiris bucks trend with today’s Developer of stem cell treatments gets its price in early underwriting By Tricia Bishop Baltimore sun reporter
August 4, 2006
“Osiris is thought to be the closest in the country to bringing a pure stem cell product to market – years ahead of its embryonic counterparts. Already, it’s selling a therapy made from donor bone that contains stem cells.”
“Today, the 14-year-old company has three drugs in five clinical trials, a bone-regeneration treatment – called Osteocel – on the market, and high hopes that Prochymal, one of its full-blown stem cell drugs, will be approved for sale next year.”
Author Profile
- Jennifer Lahl, MA, BSN, RN, is founder and president of The Center for Bioethics and Culture Network. Lahl couples her 25 years of experience as a pediatric critical care nurse, a hospital administrator, and a senior-level nursing manager with a deep passion to speak for those who have no voice. Lahl’s writings have appeared in various publications including Cambridge University Press, the San Francisco Chronicle, the Dallas Morning News, and the American Journal of Bioethics. As a field expert, she is routinely interviewed on radio and television including ABC, CBS, PBS, and NPR. She is also called upon to speak alongside lawmakers and members of the scientific community, even being invited to speak to members of the European Parliament in Brussels to address issues of egg trafficking; she has three times addressed the United Nations during the Commission on the Status of Women on egg and womb trafficking.
Latest entries
ArticleSeptember 25, 2023The Little Engine That Could
SurrogacySeptember 12, 2023Surrogacy Scandals Continue
SurrogacyJune 27, 2023When Surrogacy Goes Badly, There Are Never Any Winners
Gender IdentityMay 30, 2023Fertility Preservation in “Transgender” Children and Adolescents
